NCT02232243View on ClinicalTrials.gov

HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 1, 2018

Study Completion Date

December 1, 2018

Conditions
Solid Tumor
Interventions
DRUG

Hydroxychloroquine, 200mg twice dailiy

Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.

DRUG

Hydroxychloroquine, 400mg twice daily

Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.

Trial Locations (1)

40536

University of Kentucky, Markey Cancer Center, Lexington

All Listed Sponsors
lead

Peng Wang, MD PhD

OTHER

NCT02232243 - HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors | Biotech Hunter | Biotech Hunter